All In Biotech

Drug Trial Radar · NCT02149199

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.

A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.

Last checked: Nov 19, 2026Latest source record: Nov 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,850

Actual

Start

Jul 7, 2014

Primary completion

Aug 2, 2017

Study completion Aug 2, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline Turbuhaler® 'as needed'.

Conditions

  • Asthma

Interventions

  • budesonide/formoterol 'as needed' + budesonide placebo bidDrug

    Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment

  • terbutaline 'as needed' + placebo budesonide bidDrug

    Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment

  • budesonide bid + terbutaline 'as needed'Drug

    Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)Time frame: Weekly, up to 52 weeks

Locations

255 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Bedford Park, Australia

  • Research Site

    Concord, Australia

  • Research Site

    Maroubra, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Wollongong, Australia

  • Research Site

    Alphaville, Brazil

  • Research Site

    Botucatu, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Sorocaba, Brazil

  • Research Site

    Dupnitsa, Bulgaria

  • Research Site

    Gotse Delchev, Bulgaria

  • Research Site

    Kozloduy, Bulgaria

  • Research Site

    Pazardzhik, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Razgrad, Bulgaria

  • Research Site

    Roman, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Sandanski, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Velingrad, Bulgaria

  • Research Site

    Vratsa, Bulgaria

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Sherwood Park, Alberta, Canada

  • Research Site

    Maple Ridge, British Columbia, Canada

  • Research Site

    North Vancouver, British Columbia, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Mount Pearl, Newfoundland and Labrador, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Ajax, Ontario, Canada

Showing 40 of 255 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.